Market Research Logo

Prescription Drugs Market Research Reports & Industry Analysis

In April 2011, the Food and Drug Administration (FDA) announced a new program focused on curbing the abuse and reducing associated risks of prescription opioid painkillers. The Risk Evaluation and Mitigation Strategy (REMS) program focuses primarily on educating doctors about proper pain management, patient selection and improving patient awareness about how to use these drugs safely.

According to the White House, prescription drug abuse has become an epidemic, estimating that in 2007 alone, over 33 million Americans age 12 and older misused opioid painkillers. That same year, drug overdose in the U.S. was one of the leading causes of unintentional injury death, second only to motor vehicle accidents.

One important target of the campaign is the safe disposal of medications. In many cases, doctors have been found to prescribe larger doses of opioids than patients actually use. Many of these pills find their way onto the black market. Additionally, more than half of all non-prescribed painkiller users get their drugs from someone they know. As part of the plan, FDA wants opioid manufacturers to provide prescribing physicians with educational materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

The drugs targeted by the REMS plan include brand name products known under the generic names hydromorphone, oxycodone, morphine, oxymorphone, methadone, transdermal fentanyl, and transdermal buprenorphine.

...Show More ...Show Less


Filter your search

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Prescription Drugs Industry Research & Market Reports

  • Global Pharmaceuticals & Healthcare Q1 2018

    ... demands for new treatments with budgetary constraints. Charities and multilateral organisations are widening medicine access to those on low incomes. Patient groups are encouraging research into innovative therapeutics to reduce disease burdens. Pharmaceutical companies need ... Read More

  • Latin America Pharmaceuticals & Healthcare Q1 2018

    ... downside risks for drugmaker revenues as access to pharmaceuticals and healthcare remains a concern. Despite this, the Latin America region's high demand for medicines and regulatory advancements will maintain drugmaker interest in the long term. Read More

  • Kenya Pharmaceuticals & Healthcare Q1 2018

    ... manufacturing. High communicable disease burden, including HIV/AIDS and TB, steady economic development and the introduction of measures to improve the healthcare insurance coverage will continue to boost markets' prospects. However, the availability of finances for ... Read More

  • Myanmar Pharmaceuticals & Healthcare Q1 2018

    ... medicine production and private hospital construction to be fully funded by foreign investors, will make the country an attractive market to multinational drugmakers looking to secure a first-mover advantage in this underdeveloped pharmaceutical market. The ... Read More

  • Laos Pharmaceuticals & Healthcare Q1 2018

    ... attractiveness to multinational drugmakers. However, the Laotian economy will remain on a sustained growth trajectory, benefitting from Southeast Asian economic integration and Chinese infrastructure projects across the region, posing upside risks to healthcare and pharmaceutical ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q1 2018

    ... This indicates a low demand for high-value pharmaceutical products and with poor access to medicine, due to an underdeveloped healthcare infrastructure, we expect patented drugs sales to remain almost non-existent over the forecast. We expect ... Read More

  • Gabon Pharmaceuticals & Healthcare Q1 2018

    ... for the sale of high-value drugs by innovative drugmakers. The market dynamics are robust; however, as the gradual transition towards a chronic-disease dominated landscape is indicative of the increasing prevalence of lifestyle-related diseases in Gabon. Read More

  • Qatar Pharmaceuticals & Healthcare Q1 2018

    ... demand for healthcare and high spending per capita on medicine will underpin innovative medicines sales. That said, the country's small overall market size and extremely young population will continue to limit growth opportunities, tarnishing its ... Read More

  • Portugal Pharmaceuticals & Healthcare Q1 2018

    ... of a more robust economic recovery, the government is poised to normalise public hospitals' debt to pharmaceutical and medical device suppliers over the coming quarters. However, given high debt by public hospitals and the several ... Read More

  • Guatemala Pharmaceuticals & Healthcare Q1 2018

    ... of underdevelopment, commercial incentives for foreign drugmakers to further expand in Guatemala's pharmaceutical market will remain mainly restricted to low-cost generic drugs. Meanwhile, high levels of bureaucracy and corruption, combined with a moderate level of ... Read More

  • Middle East And North Africa Pharmaceuticals & Healthcare Q1 2018

    ... to face headwinds that challenge growth. The near-term picture remains uncertain, with macroeconomic and political instabilities challenging drugmaker revenues. However, the region's long-term prospects are bright as the expansion of healthcare coverage and infrastructure in ... Read More

  • Netherlands Pharmaceuticals & Healthcare Q1 2018

    ... the coming years driven by an ageing population and rising prevalence of chronic diseases. However, with the cost of healthcare rising, we expect the government to maintain its pro-generic stance and decrease expenses on medicines. Read More

  • Pakistan Pharmaceuticals & Healthcare Q1 2018

    ... dictate a tailored multinational company strategy in Pakistan. Nevertheless, the rising chronic disease burden, combined with government incentives to improve access to treatment, will become an increasingly important factor supporting pharmaceutical and healthcare market growth. Read More

  • Tunisia Pharmaceuticals & Healthcare Q1 2018

    ... sector any beyond, with Tunisia already boasting impressive levels of medical tourism. The next key step will be the removal of market access barriers for innovative medicines, with an uncertain and inflexible regulatory environment currently ... Read More

  • Kyrgyzstan Pharmaceuticals & Healthcare Q1 2018

    ... lack of regulatory oversight will create a challenging environment, creating a major access barrier to drugmakers. Moreover, affordability levels are low, resulting in drug demand almost exclusively within the non-branded generic and over-the-counter medicines sectors. Read More

  • Slovenia Pharmaceuticals & Healthcare Q1 2018

    ... cancer and cardiovascular diseases in particular, pose such a great burden. However, despite an attractive epidemiological profile, the country's small population and market size will somewhat act as deterrent to any major investment from multinationals. Read More

  • Uganda Pharmaceuticals & Healthcare Q1 2018

    ... with opportunities being presented for multinationals selling high-value patented drugs. On the other hand, Uganda's public healthcare sector will remain underfunded, and hence underdeveloped, with the private sector remaining the largest in terms of value. Read More

  • Musculoskeletal Drugs Market Global Briefing 2018 Including: Musculoskeletal Drugs, Muscle Relaxants, Drugs For Rheumatoid ArthritisCovering: F. Hoffmann-La Roche Ltd., GlaxosmithKline Plc., Pfizer Inc., Daiichi Sankyo Company, Limited, Abbott Laboratorie

    ... S.A., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Celgene Corporation North America was the largest region in the musculoskeletal disorders drugs market in 2017, accounting for around 32% market share. This can be attributed to the ... Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q1 2018

    ... number of upside risks for drugmaker opportunities, including expanding healthcare coverage, governments' providing investment incentives, and regulatory harmonisation, these face a number of logistical hurdles that will limit companies revenue-earning capabilities and only materialise over ... Read More

  • Pharmaceuticals Markets in China

    ... speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry ... Read More

  • Pharmaceuticals Industry Forecasts - China Focus

    ... rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s ... Read More

  • Pharmaceutical Wholesalers (EUROPEAN) - Industry Report

    ... PHARMA. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (EUROPEAN) analysis is ideal for anyone wanting to: • See the market leaders ... Read More

  • Global Paclitaxel Sales Market Report 2018

    ... top players in global and major regions, and splits the Paclitaxel market by product type and applications/end industries. In the last several years, global market of Paclitaxel developed rapidly, with an average growth rate of ... Read More

  • Global Pharma Track and Trace Solutions Market Size, Status and Forecast 2025

    ... regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Pharma Track and Trace Solutions market by product type and applications/end industries. In the last ... Read More

  • Pharmaceutical Wholesalers (GLOBAL) - Industry Report

    ... and KSK CO.,LTD.. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (GLOBAL) analysis is ideal for anyone wanting to: • See the ... Read More

< prev 1 3 4 5 6 7 8 9 10